Pacira BioSciences - PCRX Stock Forecast, Price & News

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences Stock Up 0.3 %

Shares of NASDAQ:PCRX traded up $0.17 during midday trading on Monday, hitting $57.73. 269,604 shares of the company's stock were exchanged, compared to its average volume of 509,262. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.95 and a quick ratio of 3.20. The stock has a 50 day moving average price of $56.32 and a 200-day moving average price of $64.46. The company has a market cap of $2.62 billion, a PE ratio of 70.40 and a beta of 0.85. Pacira BioSciences has a 12 month low of $45.05 and a 12 month high of $82.16.

Pacira BioSciences (NASDAQ:PCRX - Get Rating) last posted its earnings results on Wednesday, August 3rd. The company reported $0.51 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.34). Pacira BioSciences had a return on equity of 13.13% and a net margin of 6.39%. The business had revenue of $169.41 million for the quarter, compared to the consensus estimate of $169.27 million. During the same period in the previous year, the firm earned $0.60 earnings per share. The company's revenue was up 24.9% on a year-over-year basis. On average, sell-side analysts anticipate that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Analyst Ratings Changes

PCRX has been the topic of several recent analyst reports. TheStreet upgraded shares of Pacira BioSciences from a "c" rating to a "b-" rating in a report on Wednesday, August 3rd. Piper Sandler dropped their target price on shares of Pacira BioSciences from $84.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, July 21st. Finally, Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $84.00 to $76.00 and set a "buy" rating for the company in a research note on Wednesday, June 15th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $80.75.

Insider Buying and Selling

In other Pacira BioSciences news, insider Roy Winston sold 476 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $55.70, for a total value of $26,513.20. Following the transaction, the insider now directly owns 44,992 shares in the company, valued at $2,506,054.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Pacira BioSciences news, CEO David M. Stack sold 13,828 shares of the business's stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $59.85, for a total value of $827,605.80. Following the transaction, the chief executive officer now directly owns 142,251 shares in the company, valued at $8,513,722.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Roy Winston sold 476 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $55.70, for a total transaction of $26,513.20. Following the completion of the transaction, the insider now owns 44,992 shares in the company, valued at $2,506,054.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,981 shares of company stock worth $3,336,947. 6.10% of the stock is owned by insiders.